The federal health minister, Mark Butler, said the government is trying to understand a “dynamic shift that’s happening in the global pharmaceutical market” following a new agreement that will see the UK pay 25% more for new US medicines , as drugs policy experts warn the deal sets a “problematic precedent”.

Under the deal, the UK will double the percentage of GDP it allocates to buying innovative therapies from the US. The deal has led to UK experts expressing concern that the National Health Service will pay more money for new treatments, with less money left to pay for health staff and proven existing treatments.

The US says it hopes other countries will follow. NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal Read more

Asked whether the Australian govern

See Full Page